Bank Julius Baer & Co. Ltd Zurich Has $290,000 Stock Holdings in Humana Inc. (NYSE:HUM)

Bank Julius Baer & Co. Ltd Zurich trimmed its holdings in shares of Humana Inc. (NYSE:HUM) by 95.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 633 shares of the insurance provider’s stock after selling 12,462 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Humana were worth $290,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Rakuten Securities Inc. bought a new stake in Humana during the 4th quarter worth approximately $25,000. Gradient Investments LLC grew its holdings in Humana by 200.0% during the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 40 shares during the last quarter. Cetera Trust Company N.A bought a new stake in Humana during the 4th quarter worth approximately $28,000. Nvwm LLC grew its holdings in Humana by 41.0% during the 3rd quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock worth $42,000 after acquiring an additional 25 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC bought a new stake in Humana during the 4th quarter worth approximately $55,000. 92.38% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

HUM has been the topic of a number of analyst reports. Wells Fargo & Company reduced their price objective on shares of Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research note on Monday, April 8th. Deutsche Bank Aktiengesellschaft lowered shares of Humana from a “buy” rating to a “hold” rating and reduced their price objective for the company from $595.00 to $360.00 in a research note on Thursday, January 25th. Royal Bank of Canada reduced their price objective on shares of Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a research note on Thursday. Truist Financial reaffirmed a “hold” rating and issued a $550.00 price objective on shares of Humana in a research note on Friday, January 19th. Finally, UBS Group reduced their price objective on shares of Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday. Eleven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $424.50.

Humana Stock Performance

HUM opened at $305.90 on Friday. The company has a current ratio of 1.67, a quick ratio of 1.59 and a debt-to-equity ratio of 0.77. The company’s fifty day moving average price is $327.77 and its two-hundred day moving average price is $393.91. Humana Inc. has a 1-year low of $299.23 and a 1-year high of $541.21. The company has a market cap of $36.86 billion, a price-to-earnings ratio of 19.05, a PEG ratio of 1.79 and a beta of 0.45.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm had revenue of $29.61 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same quarter in the prior year, the company posted $9.38 earnings per share. The business’s revenue was up 10.7% on a year-over-year basis. On average, analysts expect that Humana Inc. will post 16.08 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 annualized dividend and a yield of 1.16%. Humana’s payout ratio is 22.04%.

Insiders Place Their Bets

In other Humana news, Director Jorge S. Mesquita acquired 545 shares of the stock in a transaction on Tuesday, February 20th. The shares were purchased at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.32% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.